Publications

Kattge, J., et al.(2020). TRY plant trait database - enhanced coverage and open access. Glob Chang Biol 26(1): 119-188.

Schulze, V. K., et al.(2020). Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. J Med Chem.

Superti-Furga, G., et al.(2020). The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nat Rev Drug Discov.

Wengner, A. M., et al.(2020). The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol Cancer Ther 19(1): 26-38.

Zhao, X. Y., et al.(2020). Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia. Nat Commun 11(1): 2992.

Friberg, A., et al.(2020). Structural Evidence for Isoform-Selective Allosteric Inhibition of Lactate Dehydrogenase A. ACS Omega 5(22): 13034-13041.

Eaton, J. K., et al.(2020). Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol 16(5): 497-506.

Berger, M., et al.(2020). Response to 'Correlation between bispectral index and age-adjusted minimal alveolar concentration' (Br J Anaesth 2020; 124:e8). Br J Anaesth 124(3): e38-e39.

Luh, L. M., et al.(2020). Prey for the Proteasome: Targeted Protein Degradation - A Medicinal Chemist s Perspective. Angew Chem Int Ed Engl.

Khan, M., et al.(2020). Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. Head Neck 42(4): 625-635.

Lefranc, J., et al.(2020). Discovery of BAY-985, a Highly Selective TBK1/IKKepsilon Inhibitor. J Med Chem 63(2): 601-612.

Luecking, U., et al.(2020). Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem.

Tarantelli, C., et al.(2020). Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Adv 4(5): 819-829.

Trunkle, C., et al.(2020). Concentration Dependence of the Unbound Partition Coefficient Kpuu and Its Application to Correct for Exposure-Related Discrepancies between Biochemical and Cellular Potency of KAT6A Inhibitors. Drug Metab Dispos 48(7): 553-562.

Mortier, J., et al.(2020). Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS(G12C). ChemMedChem 15(10): 827-832.

Brzezinka, K., et al.(2020). Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target. Cancers

Christian, S., et al.(2019). The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 33(10): 2403-2415.

Carter, A. J., et al.(2019). Target 2035: probing the human proteome. Drug Discov Today 24(11): 2111-2115.

Wang, F., et al.(2019). Synthesis, biological function and evaluation of Shikonin in cancer therapy. Fitoterapia 134: 329-339.

Grunewald, S., et al.(2019). Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer 145(5): 1346-1357.

Bosma, R., et al.(2019). Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor. Sci Rep 9(1): 7906.

Siemeister, G., et al.(2019). Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo. Clin Cancer Res 25(4): 1404-1414.

Zane, P., et al.(2019). In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development. Eur J Pharm Biopharm 142: 222-231.

Baurle, S., et al.(2019). Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis. J Med Chem 62(5): 2541-2563.

Brzezinka, K., et al.(2019). Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. J Hematol Oncol 12(1): 66.

Vriens, K., et al.(2019). Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature 566(7744): 403-406.

Hillig, R. C., et al.(2019). Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A 116(7): 2551-2560.

Wortmann, L., et al.(2019). Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo. J Med Chem 62(22): 10321-10341.

Koppitz, M., et al.(2019). Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosis. Bioorg Med Chem Lett 29(18): 2700-2705.

Werner, S., et al.(2019). Discovery and Characterization of the Potent and Selective P2X4 Inhibitor N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile. J Med Chem 62(24): 11194-11217.

Nguyen, D., et al.(2019). Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5. J Med Chem 62(2): 928-940.

Sugawara, T., et al.(2019). Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. Int J Cancer 145(5): 1382-1394.

Georgi, V., et al.(2019). Considerations for improved performance of competition association assays analysed with the Motulsky-Mahan's kinetics of competitive binding model. Br J Pharmacol 176(24): 4731-4744.

Carter, A. J., et al.(2019). Chemical Strategies for Evaluating New Drug Targets. Target Discovery and Validation: 1-24.

Schaefer, M., et al.(2019). Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol 431(24): 4817-4833.

Gelato, K. A., et al.(2018). Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition. Oncogene 37(4): 512-521.

Klutzny, S., et al.(2018). PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling. Cell Death Dis 9(2): 192.

de Witte, W. E. A., et al.(2018). In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations. Br J Pharmacol 175(21): 4121-4136.

Heroven, C., et al.(2018). Halogen-Aromatic pi Interactions Modulate Inhibitor Residence Times. Angew Chem Int Ed Engl 57(24): 7220-7224.

Izzo, F., et al.(2018). Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides. Chemistry 24(37): 9295-9304.

Muller, S., et al.(2018). Donated chemical probes for open science. Elife 7.

Moller, C., et al.(2018). Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies. ChemMedChem 13(21): 2271-2280.

Georgi, V., et al.(2018). Binding Kinetics Survey of the Drugged Kinome. J Am Chem Soc 140(46): 15774-15782.

Paul, J., et al.(2017). Simultaneous Inhibition of PI3Kdelta and PI3Kalpha Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kappaB and AKT. Cancer Cell 31(1): 64-78.

Eikelboom, J. W., et al.(2017). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 377(14): 1319-1330.

Willuda, J., et al.(2017). Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther 16(5): 893-904.

Pusch, S., et al.(2017). Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol 133(4): 629-644.

Ellermann, M., et al.(2017). Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target. ACS Chem Biol 12(8): 1986-1992.

Regan, J. L., et al.(2017). Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. Cell Rep 21(10): 2813-2828.

Schutte, M., et al.(2017). Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun 8: 14262.

Schuetz, D. A., et al.(2017). Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discov Today 22(6): 896-911.

Dann, G. P., et al.(2017). ISWI chromatin remodellers sense nucleosome modifications to determine substrate preference. Nature 548(7669): 607-611.

Fernandez-Montalvan, A. E., et al.(2017). Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action. ACS Chem Biol 12(11): 2730-2736.

Lucking, U., et al.(2017). Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem 12(21): 1776-1793.

Klutzny, S., et al.(2017). Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death. Cell Death Dis 8(3): e2709.

Schmid, E., et al.(2017). Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays. Biotech Histochem 92(6): 425-435.

Goth, M., et al.(2017). Critical Evaluation of Native Electrospray Ionization Mass Spectrometry for Fragment-Based Screening. ChemMedChem 12(15): 1201-1211.

Georgi, V., et al.(2017). Binding kinetics in drug discovery - A current perspective. Front Biosci

Bouche, L., et al.(2017). Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains. J Med Chem 60(9): 4002-4022.

Politz, O., et al.(2017). BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. Int J Cancer 140(2): 449-459.

Izzo, F., et al.(2017). A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides. Chemistry 23(60): 15189-15193.

Johansson, C., et al.(2016). Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol 12(7): 539-545.

Gottwald, M., et al.(2016). Public-Private Partnerships in Lead Discovery: Overview and Case Studies. Arch Pharm

Baron, A. P., et al.(2016). Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524. Elife 5.

von Nussbaum, F., et al.(2016). Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model. ChemMedChem 11(2): 199-206.

Wengner, A. M., et al.(2016). Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Mol Cancer Ther 15(4): 583-592.

Kapoor, K., et al.(2016). Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides. Proc Natl Acad Sci U S A 113(17): 4711-4716.

Rodriguez, O., et al.(2016). Manganese-Enhanced Magnetic Resonance Imaging as a Diagnostic and Dispositional Tool after Mild-Moderate Blast Traumatic Brain Injury. J Neurotrauma 33(7): 662-671.

Sykes, D. B., et al.(2016). Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 167(1): 171-186 e115.

Langer, G.(2016). Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays. Handb Exp Pharmacol 232: 171-190.

Prinz, F., et al.(2016). Functional and Structural Characterization of Bub3.BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells. J Biol Chem 291(21): 11252-11267.

Hernando, H., et al.(2016). EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes. Mol Cancer Ther 15(2): 287-298.

Arlt, A., et al.(2016). Discovery of Rigidified alpha,beta-Unsaturated Imines as New Resistance-breaking Insecticides for Malaria Vector Control. Chimia

Ferreira de Freitas, R., et al.(2016). Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor. J Med Chem 59(3): 1176-1183.

Scott, W. J., et al.(2016). Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem 11(14): 1517-1530.

Eggert, E., et al.(2016). Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. J Med Chem 59(10): 4578-4600.

Brychta, N., et al.(2016). Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. Clin Chem 62(11): 1482-1491.

Schiele, F., et al.(2016). Corrigendum to A universal, homogenous assay for high throughput determination of binding kinetics [Anal. Biochem. 468 (2015) 42-49]. Anal Biochem 514: 1.

Ayaz, P., et al.(2016). Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. ACS Chem Biol 11(6): 1710-1719.

Nederpelt, I., et al.(2016). Characterization of 12 GnRH peptide agonists - a kinetic perspective. Br J Pharmacol 173(1): 128-141.

Renaud, J. P., et al.(2016). Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov 15(10): 679-698.

Koo, S. J., et al.(2016). ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget 7(43): 70323-70335.

Mittag, S., et al.(2016). A novel role for the tumour suppressor Nitrilase1 modulating the Wnt/beta-catenin signalling pathway. Cell Discov 2: 15039.

Arrowsmith, C. H., et al.(2015). The promise and peril of chemical probes. Nat Chem Biol 11(8): 536-541.

Jung, M., et al.(2015). Targeting BET bromodomains for cancer treatment. Epigenomics 7(3): 487-501.

Schmitz, A. A., et al.(2015). Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands. Nat Rev Drug Discov 14(4): 294.

Luense, S., et al.(2015). Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors. J Biomol Screen 20(2): 190-201.

Hartung, I. V., et al.(2015). Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles. ChemMedChem 10(12): 2004-2013.

von Nussbaum, F., et al.(2015). Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem 10(7): 1163-1173.

Rotgeri, A., et al.(2015). Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys. Hum Reprod 30(2): 308-314.

Schulze, J., et al.(2015). Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4. J Biomol Screen 20(2): 180-189.

Schiele, F., et al.(2015). A universal homogeneous assay for high-throughput determination of binding kinetics. Anal Biochem 468: 42-49.

Wenzel, C., et al.(2015). A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates. Exp Cell Res 339(1): 35-43.

Barucker, C., et al.(2014). Nuclear translocation uncovers the amyloid peptide Abeta42 as a regulator of gene transcription. J Biol Chem 289(29): 20182-20191.

Zeidler, C., et al.(2014). Heterozygous FGF8 mutations in patients presenting cryptorchidism and multiple VATER/VACTERL features without limb anomalies. Birth Defects Res A Clin Mol Teratol 100(10): 750-759.

Gallenkamp, D., et al.(2014). Bromodomains and their pharmacological inhibitors. ChemMedChem 9(3): 438-464.

Golfier, S., et al.(2014). Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13(6): 1537-1548.

Jung, M., et al.(2014). Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem 289(13): 9304-9319.

Nguyen, U. T., et al.(2014). Accelerated chromatin biochemistry using DNA-barcoded nucleosome libraries. Nat Methods 11(8): 834-840.

Wenzel, C., et al.(2014). 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res 323(1): 131-143.

Lucking, U., et al.(2013). The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluorome thyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer. ChemMedChem 8(7): 1067-1085.

Follmann, M., et al.(2013). The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 52(36): 9442-9462.

Hartung, I. V., et al.(2013). Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories. Bioorg Med Chem Lett 23(8): 2384-2390.

Kumar, V., et al.(2013). Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes. Biochemistry 52(20): 3601-3608.

Wehrman, T., et al.(2013). EphB4 cellular kinase activity assayed using an enzymatic protein interaction system. Assay Drug Dev Technol 11(4): 237-243.

Jemaa, M., et al.(2013). Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ 20(11): 1532-1545.

Graham, K., et al.(2012). Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. J Med Chem 55(22): 9510-9520.

Brockschnieder, D., et al.(2012). Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-beta. J Nucl Med 53(11): 1794-1801.

Gorges, T. M., et al.(2012). Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 12: 178.

Gorges, T. M., et al.(2012). Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. Biomarkers 17(6): 498-506.

Siemeister, G., et al.(2012). BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther 11(10): 2265-2273.

Schulz, M. N., et al.(2011). A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. Acta Crystallogr D Biol Crystallogr 67(Pt 3): 156-166.

Schottelius, A. J., et al.(2010). The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol 130(2): 481-491.

Martin, F., et al.(2010). Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 285(29): 22651-22657.

Scheich, C., et al.(2010). Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C. J Med Chem 53(23): 8362-8367.

Hilal, T., et al.(2010). A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment. J Biomol Screen 15(3): 268-278.

Langer, G., et al.(2010). A critical review of fundamental controversies in the field of GPR30 research. Steroids 75(8-9): 603-610.

Amberger, H. D., et al.(2009). Synthesis, molecular, and electronic structure of (eta(8)-C8H8)Ln(scorpionate) half-sandwich complexes: an experimental key to a better understanding of f-element-cyclooctatetraenyl bonding. Inorg Chem 48(2): 760-772.

Hoffmann, J., et al.(2009). Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 11(2): 158-166.

Missner, E., et al.(2009). Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. Chembiochem 10(7): 1163-1174.

Werner, S., et al.(2009). Fluorous parallel synthesis of a piperazinedione-fused tricyclic compound library. J Comb Chem 11(3): 452-459.

Ziera, T., et al.(2009). Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J 23(11): 3936-3946.

Related Topics